Shanghai, China – July 28, 2025 – Neuco United Co., Limited. ("Neuco United") and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") today announced the signing of an exclusive licensing agreement for the manufacturing and commercialization of AR1001 in Greater China, encompassing in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR.

From 26 to 28 July, the largest, most professional, and most influential top-tier event in the global artificial intelligence (AI) field, the 2025 World AI Conference & High-Level Meeting on Global AI Governance (WAIC 2025), was held, once again drawing worldwide AI attention to Shanghai.

In July 2025, Henlius celebrates the fifth anniversary of the global approval of its blockbuster breast cancer therapy, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac^® in Europe). As the first "China-developed" monoclonal antibody (mAb) biosimilar approved in China, the EU, and the U.S., HANQUYOU has been launched in over 50 countries and regions worldwide, with more than 7.5 million units shipped globally. Its out-licensing covers over 100 countries and regions, benefiting more than 260,000 patients worldwide. Over the past five years, Henlius has been deeply engaged in the breast cancer field—starting with HANQUYOU, the first Chinese trastuzumab biosimilar; then with HANNAIJIA (neratinib), the leader in extended adjuvant therapy; and now with an innovative pipeline covering more subtypes and treatment stages—committed to building a full-course, all-domain, global breast cancer treatment ecosystem, with the mission of "leaving no breast cancer patient behind".

Recently, Morgan Stanley Capital International (MSCI), a leading global index provider, released its latest annual ESG (Environmental, Social, and Governance) ratings. Fosun Pharma ascended to an 'AA' rating, highlighting its exceptional performance in sustainable development, reflecting its leadership position within the domestic pharmaceutical industry and underscoring its ongoing advancements in ESG governance and execution.

2025 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer(IASLC)  will be held from September 6-9 in Barcelona, Spain. At the conference, Henlius will showcase 10 latest results from its innovative products on lung cancer, which includes 3 oral presentations and 2 poster tours, covering updated phase 1 clinical data for PD-L1 ADC HLX43, the results(first release) from ASTRUM-002, a phase 3 clinical trial of serplulimab (anti-PD-1 monoclonal antibody) in the first line treatment of advanced non-squamous non small cell lung cancer (NSCLC) as oral presentation, along with further research findings on serplulimab in lung cancer, making it the Chinese biopharmaceautical with most oral presentations.

On July 21, 2025, the Board of Directors of Club Med Holding is pleased to announce the appointment of Stéphane Maquaire as the President and Chief Executive Officer of Club Med Holding, effective immediately.

On 18 July 2025, – Standard & Poor’s (S&P), one of the world’s leading international credit rating agencies, initiated coverage and assigned Fidelidade – Companhia de Seguros, S.A. and its reinsurance company, Fidelidade RE – Companhia de Resseguros, S.A., long-term Issuer Credit Ratings (ICR) and Financial Strength Ratings (FSR) of ‘A’, with a stable outlook.

(July 9, 2025, Shanghai, China）— On 9 July, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; Stock Code: 600196.SH, 02196.HK), announced that its self-developed MEK1/2 selective inhibitor Fu Mai Ning (generic name: Luvometinib Tablets; the “Drug”) has entered Phase 3 clinical trial for the treatment of pediatric low-grade glioma (pLGG) in China (excluding Hong Kong SAR, Macau SAR and Taiwan region).

Recently, Henlius has achieved significant advancement in the global development of HLX43, its innovative programmed death-ligand 1 (PD-L1) targeting antibody-drug conjugate (ADC), which has already been approved by the China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), Australia Therapeutic Goods Administration (TGA) and Japan`s Pharmaceuticals and Medical Devices Agency (PMDA) to initiate phase 2 multi-regional clinical trial in patients with advanced non-small cell lung cancer (NSCLC). Additionally, the first patient dosing has been completed in China. To date, no PD-L1 targeting ADC has been approved for marketing globally. HLX43 is the first PD-L1 ADC progressed to phase 2 clinical trial development globally.